Conference Highlights from the 2026 SOHO and IMS meetings

Program Overview

This conference coverage activity reviews the latest evidence for CELMoDs for the treatment of multiple myeloma, highlighting recently presented efficacy and safety findings from the 2026 SOHO and IMS meetings. With a recent FDA approval for iberdomide, and with mezigdomide under investigation in late-stage clinical trials, clinicians need to stay up to date on how to consider these agents for potential use in multiple myeloma treatment. In the concluding discussion, multiple myeloma expert Dr. Nisha Joseph and community hematologist/oncologist Dr. Samantha Shams explore how CELMoDs may influence treatment sequencing and discuss the practical implications of an expanding treatment landscape for community oncology practice.

Target Audience

This educational series is intended to provide continuing medical education (CME)/continuing education (CE) to health care clinicians involved in the treatment of hematologic malignancies, especially multiple myeloma (MM), including medical oncologists, hematologists, hematology/oncology (hem/onc) fellows, and advanced practice providers (APPs).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Review the most recent clinical trial data on FDA-approved and emerging treatments for multiple myeloma (MM), such as the novel CELMoD treatments, emerging from recent hematology/oncology conferences
2. Describe where novel CELMoD therapies would fit into future treatment algorithms for MM
3. Identify strategies for incorporating FDA-approved and emerging CELMoD therapy into personalized medicine approaches in MM, based on the latest clinical data and potential future FDA approval 

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Nisha Joseph, MD:

• Consulting Fees: AstraZeneca, Bristol Myers Squibb, Cell Centriq, GSK, J&J Oncology, Legend, Pfizer, Regeneron

Samantha R. Shams, MD:

• Nothing to disclose

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Contact Information

For information about this program, please contact us at info@exchangecme.com.